Gland Pharma Share Price Target 2027: Rs 3,812 Base
- November 17, 2026
- Posted by: Chaitanya Auti
- Category: Market
Gland Pharma share price Rs 3,385.90 (17 November 2026). Base target Rs 3,812, bull Rs 4,611, downside risk Rs 2,646. PE 44.16. 52W range Rs 1,573.60 to Rs 3,429.00.
Quick Answer
The Gland Pharma share price target for 2027 is Rs 3,812, about 12.6% above the current price of Rs 3,385.90. The bull case is Rs 4,611, and the downside risk level, which is not a target, is Rs 2,646. The base case assumes earnings per share grow 15.2% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 44.16. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Gland Pharma target price for 2027 should start with where the stock sits today. At Rs 3,385.90 on 17 November 2026, it is 1.3% below its 52-week high of Rs 3,429.00 and 115.2% above its 52-week low of Rs 1,573.60. That range spans 118% from low to high, so the entry point matters as much as the Gland Pharma price forecast itself.
This article builds the Gland Pharma share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.
Click Here – Get Free Investment Predictions
Gland Pharma Stock Analysis: Company Overview and Key Stats
Gland Pharma (NSE: GLAND) has a market capitalisation of Rs 54,577 crore. In FY26 it reported revenue of Rs 6,747 crore and net profit of Rs 1,027 crore. The table collects the figures the Gland Pharma share price target is built on.
| Metric | Value |
|---|---|
| Company | Gland Pharma |
| NSE Ticker | GLAND |
| CMP (17 November 2026) | Rs 3,385.90 |
| 52-Week High | Rs 3,429.00 |
| 52-Week Low | Rs 1,573.60 |
| Market Cap | Rs 54,577 crore |
| PE Ratio (TTM) | 44.16 |
| Industry PE | 40.55 |
| Price to Book | 5.11 |
| Return on Equity | 11.57% |
| Debt to Equity | 0.02 |
| EPS (TTM) | Rs 74.90 |
| Dividend Yield | 0.60% |
| 12-Month Base Target | Rs 3,812 |
| Bull Case | Rs 4,611 |
| Downside Risk Level (not a target) | Rs 2,646 |
Why Is Gland Pharma Share Price Target Set at Rs 3,812 for 2027?
The arithmetic is short. Trailing EPS of Rs 74.90 grown for one year gives a forward EPS estimate of Rs 86.32, and multiplying it by the unchanged PE of 44.16 gives the Rs 3,812 base-case Gland Pharma stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Gland Pharma Target Price: Five Years of Results
Gland Pharma grew revenue from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew more slowly, from Rs 1,212 crore to Rs 1,027 crore (-4.0% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 4,624.65 | 1,211.66 | 73.64 | 0.00 |
| FY23 | 3,865.06 | 781.04 | 47.43 | 0.00 |
| FY24 | 5,834.96 | 772.46 | 46.89 | 20.00 |
| FY25 | 5,830.11 | 698.53 | 42.40 | 18.00 |
| FY26 | 6,746.98 | 1,027.32 | 62.28 | 20.00 |
FY26 revenue growth was 15.7%, faster than the four-year average of 9.9%, and net profit moved up 47.1%. EPS rose from Rs 46.89 in FY24 to Rs 62.28 in FY26. The FY27 outlook for the Gland Pharma price target depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Gland Pharma converted 15.2% of FY26 revenue into net profit, against 12.0% in FY25, within a five-year range of 12.0% to 26.2%. EBITDA margin was 28.5% in FY26 versus 25.4% in FY25.
In the September 2026 quarter, revenue was Rs 1,903 crore, up 21.1% from the same quarter a year earlier, while net profit of Rs 290.76 crore was up 58.3%. EBITDA came in at Rs 553.09 crore, up 38.9% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Gland Pharma stock target holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.02, and shareholders’ equity grew from Rs 7,158 crore in FY22 to Rs 10,358 crore in FY26. Operating cash flow in FY26 was Rs 1,031 crore against capital expenditure of Rs 494.43 crore, leaving free cash flow of Rs 536.96 crore, or 1.0% of the current market capitalisation. In FY25 free cash flow was Rs 520.56 crore.
Valuation Check for the Gland Pharma Stock Target: PE, Price to Book and ROE
At a PE of 44.16 against an industry PE of 40.55, Gland Pharma trades in line with its industry. Price to book is 5.11 on a book value of Rs 647.57 per share, and return on equity is 11.57%. A PE of 44.16 equals an earnings yield of 2.3%, and the FY26 dividend of Rs 20.00 per share gives a yield of 0.60%.
Shareholding Pattern and Institutional Holding
Promoters held 45.75% of Gland Pharma in September 2026, and promoter holding fell from 51.83% in September 2025 to 45.75% in September 2026. Foreign institutional investors (FII) held 10.36% and domestic institutions (DII) held 33.21%, which puts total institutional holding at 43.57%. FII holding rose from 7.91% in September 2025 to 10.36% in September 2026. Public shareholders own the remaining 10.67%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Gland Pharma Share Price Targets for the Short Term and 12 Months
Short Term Gland Pharma Stock Target Levels: Technical Setup
At Rs 3,385.90 on 17 November 2026, Gland Pharma trades above its 50-day simple moving average of Rs 3,031.95 and above its 200-day exponential moving average of Rs 2,527.04. The 14-day RSI reads 78.6, which is overbought territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 3,429.00 (52-week high) and the nearest support is Rs 3,031.95 (50-day simple moving average). A sustained move above Rs 3,429.00 would improve the short-term setup, while a close below Rs 3,031.95 would shift attention to the next support.
12 Month Gland Pharma Target Price for 2027
The 12-month target of Rs 3,812 means a move of 12.6% up from Rs 3,385.90 over the next 12 months. It would also push the stock above its 52-week high of Rs 3,429.00. Anyone checking the Gland Pharma share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.
How EPS Growth and PE Multiple Change the Gland Pharma Target Price
| EPS Growth | PE 35.33 | PE 44.16 | PE 50.78 |
|---|---|---|---|
| 0.0% (EPS Rs 74.90) | Rs 2,646 | Rs 3,308 | Rs 3,803 |
| 15.2% (EPS Rs 86.32) | Rs 3,050 | Rs 3,812 | Rs 4,383 |
| 21.2% (EPS Rs 90.81) | Rs 3,208 | Rs 4,010 | Rs 4,611 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Gland Pharma price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Gland Pharma Stock Target in 2027
Bull Case Rs 4,611
The bull case Gland Pharma price target needs EPS growth of 21.2%, which lifts forward EPS to Rs 90.81, and a PE multiple that rises 15% to 50.78. That gives Rs 4,611, 36.2% above the current price and above the 52-week high of Rs 3,429.00, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 2,646
The downside risk level is not a target. It assumes EPS stays flat at Rs 74.90 and the PE falls 20% to 35.33. That gives Rs 2,646, 21.9% below the current price and above the 52-week low of Rs 1,573.60.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 21.2% | 50.78 | Rs 4,611 | +36.2% |
| Base Case | 15.2% | 44.16 | Rs 3,812 | +12.6% |
| Downside Risk | 0.0% | 35.33 | Rs 2,646 | -21.9% |
Key Risks to the Gland Pharma Target Price for 2027
Growth Slowdown Risk for the Gland Pharma Price Target
Revenue in the September 2026 quarter was up 21.1% year on year, and FY26 revenue growth was 15.7%. If growth slows from here, the EPS estimate behind the Gland Pharma stock target will need revising.
Liquidity and Size Risk
Gland Pharma has a market capitalisation of Rs 54,577 crore. Institutional holding is 43.57%, and promoters hold 45.75%. A company of this size trades with deep liquidity, so entry and exit are rarely a problem, and the larger risk is paying too much for slow earnings growth.
Valuation and Margin Risk
Net margin was 15.2% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 44.16 versus an industry PE of 40.55, a de-rating toward the downside-risk PE of 35.33 would cut the price even if earnings hold.
Market and Technical Risk
Technical indicators add short-term risk: the 14-day RSI is 78.6 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time.
How to Invest in Gland Pharma
Start with the live price and volume. Any Gland Pharma share price target is only as current as the data behind it, and the data here is as of 17 November 2026, so refresh the Rs 3,385.90 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Gland Pharma’s PE, ROE, debt and shareholding in one place.
Check Gland Pharma fundamentals on the Univest Screener
Then compare the three Gland Pharma target price scenarios with your own view. If you expect EPS growth below 15.2%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Gland Pharma live price and get daily stock recommendations.
Conclusion
The Gland Pharma share price target for 2027 is Rs 3,812 in the base case, with Rs 4,611 as the bull case. The support for that view is arithmetic you can check: EPS grew 15.2% a year over FY24 to FY26, and the stock trades at a PE of 44.16. The risks are equally concrete, including a valuation that can de-rate if growth disappoints and a downside scenario that cuts the price 22% if earnings stall. Use these numbers as a framework for judging the Gland Pharma price target, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Gland Pharma Share Price Target 2027
What is the Gland Pharma share price target for 2027?
Ans. The base-case Gland Pharma share price target for 2027 is Rs 3,812, which is 12.6% above the price of Rs 3,385.90 on 17 November 2026. The bull case is Rs 4,611 and the downside risk level, which is not a target, is Rs 2,646. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.
What is the Gland Pharma share price today?
Ans. As of 17 November 2026, before market open, Gland Pharma (NSE: GLAND) is quoted at Rs 3,385.90, which is its last closing price from the previous session. That is 1.3% below the 52-week high of Rs 3,429.00 and 115.2% above the 52-week low of Rs 1,573.60. The market capitalisation of Rs 54,577 crore places it among large-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.
Is Gland Pharma a buy or sell at the current price?
Ans. The data points both ways. On the positive side, EPS has grown 15.2% a year over FY24 to FY26 and the base case implies 12.6% upside; on the cautious side, the stock sits 1.3% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 2,646 is 22% below the current price. Whether Gland Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.
What are the bull case target and downside risk level for Gland Pharma shares?
Ans. The bull case in the Gland Pharma share price target for 2027 is Rs 4,611, which assumes 21.2% EPS growth and a PE of 50.78, a 15% re-rating from today’s multiple. That is 36.2% above the current price and above the 52-week high of Rs 3,429.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 2,646, which assumes flat EPS and a PE of 35.33, 20% lower than today. It sits 21.9% below the current price and above the 52-week low of Rs 1,573.60, and it marks a risk to watch, not a target.
What are the main risks to the Gland Pharma price target?
Ans. Four risks matter most for the Gland Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. The market capitalisation of Rs 54,577 crore means liquidity is deep, so the bigger risk is paying a full price for slow earnings growth. A fall to the downside-risk PE of 35.33 would cut the price even if earnings hold.
What is the PE ratio of Gland Pharma and how does it compare with the industry?
Ans. The PE ratio of Gland Pharma is 44.16, against an industry PE of 40.55, which is a level close to the industry. Price to book is 5.11 and return on equity is 11.57%, and the PE equals an earnings yield of 2.3%. The base case holds the PE unchanged, so the Gland Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.
Who owns Gland Pharma, and what is the promoter holding?
Ans. Promoters held 45.75% of Gland Pharma in September 2026. FII held 10.36%, DII held 33.21% and the public held 10.67%. Together the two institutional groups hold 43.57%. Shareholding is filed every quarter, so it is worth rechecking after each result.
What were Gland Pharma’s latest quarterly results?
Ans. In the September 2026 quarter, Gland Pharma reported revenue of Rs 1,903 crore (up 21.1% year on year) and net profit of Rs 290.76 crore (up 58.3%). For comparison, FY26 full-year revenue growth was 15.7% and net profit moved up 47.1%. Each new quarter either supports or weakens the EPS growth of 15.2% assumed in the base case.